Osteoporosis Management
Introduction to Osteoporosis Treatment
- The American College of Physicians recommends romosozumab for postmenopausal women with primary osteoporosis who have a very high risk of fracture, as it significantly reduces vertebral and clinical fracture risk compared to other treatments 1
- Osteoporosis treatment aims to reduce fracture risk, with the American College of Physicians recommending oral bisphosphonates as first-line treatment, followed by denosumab as an injectable first-line option, and anabolic agents reserved for high-risk patients or those who have failed other treatments 1, 2, 3
Patient Selection and Fracture Risk Assessment
- Postmenopausal women with primary osteoporosis who have very high fracture risk, defined by older age, recent fracture, history of multiple clinical osteoporotic fractures, multiple risk factors for fracture, and failure of other available osteoporosis therapy, are eligible for romosozumab treatment 1
- Treatment options are based on fracture risk, with the following indications:
| Treatment | Indication |
|---|---|
| Oral bisphosphonates | High fracture risk (FRAX ≥20% for major osteoporotic fracture or ≥3% for hip fracture) |
| IV bisphosphonate or denosumab | Contraindication for oral bisphosphonates |
| Anabolic agents | Very high fracture risk (prior fracture, T-score ≤-3.5, FRAX ≥30% for major osteoporotic fracture or ≥4.5% for hip fracture) |
- Vertebral fractures significantly increase the risk of subsequent fractures, and a history of glucocorticoid use increases osteoporosis risk, highlighting the importance of fracture assessment beyond just BMD and considering underlying metabolic bone disease 6, 7, 8
Treatment Regimen and Efficacy
- Romosozumab reduces the risk of new vertebral fractures by 73% at 12 months compared to placebo, and when followed by antiresorptive therapy, the fracture reduction benefits persist with a 75% lower risk of vertebral fractures at 24 months 1
- Denosumab is recommended as a second-line treatment after bisphosphonates, particularly when oral bisphosphonates are contraindicated, and significantly increases bone mineral density (BMD) at the lumbar spine, femoral neck, and total hip, with reported increases of 5.80%, 2.07%, and 2.28%, respectively 9, 1
- Oral bisphosphonates, such as alendronate, are indicated for patients with osteoporosis (T-score ≤ -2.5) or at high risk of fracture, with a mechanism of action involving inhibition of osteoclast activity, reducing bone resorption without directly inhibiting bone formation 1, 2, 3
Lifestyle Modifications and Supplementations
- Optimizing calcium and vitamin D intake with lifestyle modifications, including regular weight-bearing exercise, smoking cessation, limiting alcohol intake, and fall prevention strategies, is recommended for individuals with osteopenia and a low risk of fracture, with supplementing vitamin D 800-1000 IU daily and calcium 1000-1200 mg daily to achieve optimal levels, and a target serum level ≥20 ng/ml 3, 10, 11, 7, 12
- The American College of Rheumatology recommends calcium supplementation of 1,000-1,200 mg/day (diet plus supplements) and vitamin D supplementation of 600-800 IU/day, with the recommended daily doses of calcium and vitamin D as follows:
| Supplement | Recommended Daily Dose |
|---|---|
| Calcium | 1,000-1,200 mg |
| Vitamin D | 800-1,000 IU |
- Weight-bearing and resistance training exercises, smoking cessation, limiting alcohol consumption, and maintaining a healthy weight are recommended to reduce fracture risk, alongside alendronate medication, with consideration of a drug holiday after 5 years of therapy, unless there is a strong indication for continued treatment 10, 13, 9, 10, 14, 1
Safety and Adverse Effects
- Romosozumab is associated with an increased risk of cardiovascular events compared with alendronate, with a hazard ratio of 1.9 1
- The treatment is not indicated for men with osteoporosis due to insufficient evidence 1
- Cardiovascular risk factors should be considered before initiating romosozumab therapy due to potential increased cardiovascular risk 1
Cost Considerations and Monitoring
- Romosozumab is significantly more expensive than bisphosphonates, with an average annual cost per Medicare beneficiary of $5,574 compared to $39-$2,700 for bisphosphonates 1
- Bone mineral density should be reassessed in 2 years, and vitamin D levels and fracture risk should be monitored, with follow-up FRAX assessment every 1-2 years to assess treatment efficacy and adherence 11, 15, 9, 10, 7
- Preoperative testing with DEXA scan (T-score < -2.5) is recommended to assess bone mineral density and predict increased risk of postoperative adverse events in individuals with spinal issues, particularly men over 70 years of age with risk factors, according to the Congress of Neurological Surgeons and American College of Physicians 2, 3